Management of patients with chronic obstructive pulmonary disease (COPD) during COVID-19

COPD is one of the risk factors for contracting COVID-19. Good management of patients, appropriate treatment with inhaled preparations, including inhaled glucocorticosteroids, with simultaneous monitoring concomitant infections, and the use of vaccinations allow to reduce the risk of developing COVID-19. At the same time, it is necessary to limit the performance of spirometric tests to reduce the probability of SARS-CoV-2 infection. In the case of a confirmed infection, it is necessary to continue basic treatment, with strict adherence to the recommended dosage of drugs, which may significantly protect the patient against post-inflammatory fibrosis in the pulmonary parenchyma.